Focus areas The plan developed under subsection (a) shall address the following: (A) Detection and management of patients with emerging and high-consequence infections identified in the R&D Blueprint Priority Disease List of the World Health Organization, including novel emerging unknown pathogens classified as Disease X . (B) Improved point-of-care, point-of-need, and next-generation early detection diagnostics linked to disease surveillance, response planning, and information sharing networks. (C) Evidence-based, best-practice clinical management protocols that include pre-specified data collection and analysis plans that are specifically tailored for enhanced survival of infectious disease casualties and near-time data generation in low-resource conditions. (D) Enhanced infection prevention and control standards, guidelines, and training, including new technologies for protecting health care workers. (E) Improved capability for medical evacuation of patients with high-consequence infections. (F) Infectious disease emergency response teams to provide supplemental expertise and capability for dangerous pathogen infections patient management and movement in forward environments or in higher-level military medical treatment facilities. (G) Acceleration of research and development of medical countermeasures, therapeutics, and vaccines against high-consequence infections, including the development of clinical trial networks capable of generating critical supplemental human data in support of licensure applications administered by the Food and Drug Administration. (H) Coordinated and rapid manufacturing response capacity and capabilities, using regional, flexible, scalable technologies and facilities, leveraging successful medical countermeasure development and manufacturing models implemented in the Department of Health and Human Services and other departments of the Federal Government. (2) Scope For each area specified in paragraph (1), the plan shall include— (A) milestones and actions that can be carried out in